Important Information regarding Janssen/Johnson & Johnson (J&J) COVID-19 Vaccine
Important Information regarding Janssen/Johnson & Johnson (J&J) COVID-19 Vaccine On July 13, 2021, the U.S. Food and Drug Administration (FDA) announced revisions to the Emergency Use Authorization (EUA) fact sheets for the Janssen/Johnson & Johnson (J&J) COVID-19 vaccine to include information regarding an observed increased risk of Guillain-Barre Syndrome (GBS) after administration of the vaccine.
